Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1118

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1118
---
 This patent protects our core Contingent AI technology, which allows
us to simultaneously process multiple types of biomedical and experimental data, resulting in a unique method for the application of AI
across therapeutic development. This method is applied in multiple components of the BioSymetrics platform and has been applied in projects
with pharmaceutical partners.

13

On June 17, 2020, a patent titled
“Allogeneic T-Cell-Based HIV Vaccine to Induce Cellular and Humoral Immunity”, US 2021/0030795 A1 for the composition and
method of use concepts for RENB-HV-12. was filed. The Company owns this patent application, through assignment as of September 28, 2021.

In-Licensed Technology

Trade Secrets and Proprietary Know-How

In addition to intellectual property
protected by patents and copyrights, we have trade secrets and proprietary know-how relating to our products, production processes, and
future strategies.

Competition

Renovaro Cube operates in a highly
competitive market with several companies developing AI-driven diagnostic platforms for early disease detection and personalized medicine.
Key competitors include Grail, Freenome, and Owkin, each utilizing advanced AI and machine learning to analyze multi-omic data for cancer
detection. While these companies focus primarily on specific diagnostic approaches, Renovaro Cube differentiates itself through its unique,
disease-agnostic AI platform that integrates various molecular data sources for differential diagnosis. Our platform’s explainable
AI system, capable of providing actionable insights and personalized treatment options, offers a distinct advantage. Despite the crowded
landscape, Renovaro Cube’s scalable technology, multi-omics capabilities, and ability to process diverse biopsy sources position
it as a versatile leader in precision diagnostics, allowing us to address a broader range of clinical and research needs.

BioSymetrics similarly operates
in a highly competitive market with companies including Recursion Pharma and insitro also focused on phenotype-based profiling using in
vitro cellular profiling and AI. While similar in concept, Recursion and insitro’s models provide evidence on cellular, but
not multicellular or multi-organ phenotypes, so we feel our platform is differentiated, specifically when investigating behavioral and
neurological diseases. Similarly, while murine models are broadly accepted as being relevant for the study of neurological disorders,
their experimental throughput is highly limited, and turnaround times for experimentation can be on the scale of months, resulting in
a substantial experimental cost. The biggest difference is scale